Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205

被引：1
|
作者：
von Wichert, G.
Hoehler, T.
Schimanski, C. C.
Moehler, M. H.
Hofheinz, R.
Kanzler, S.
Hinke, A.
Seufferlein, T.
Siebler, J.
Hochhaus, A.
Arnold, D.
Hallek, M.
Hacker, U. T.
机构：
[1] Univ Ulm, D-89069 Ulm, Germany
[2] Prosper Hosp Recklinghausen, Recklinghausen, Germany
[3] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
[4] Univ Med Mannheim, Interdisciplinary Tumour Ctr Mannheim, Day Treatment Ctr, Mannheim, Germany
[5] Leopoldina Krankenhaus, Schweinfurt, Germany
[6] WiSP Res Inst, Langenfeld, Germany
[7] Univ Halle Wittenberg, D-06108 Halle, Saale, Germany
[8] Univ Klinikum Erlangen, Erlangen, Germany
[9] Univ Klinikum Jena, Jena, Germany
[10] Univ Canc Ctr Hamburg, Hubertus Wald Tumor Ctr, Hamburg, Germany
[11] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med 1, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3583
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    Hoehler, T.
    von Wichert, G.
    Schimanski, C.
    Kanzler, S.
    Moehler, M. H.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hofheinz, R.
    Hacker, U. T.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413
  • [2] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    T Hoehler
    G von Wichert
    C Schimanski
    S Kanzler
    M H Moehler
    A Hinke
    T Seufferlein
    J Siebler
    A Hochhaus
    D Arnold
    M Hallek
    R Hofheinz
    U T Hacker
    [J]. British Journal of Cancer, 2013, 109 : 1408 - 1413
  • [3] A phase ii study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer
    Bendell, J.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Vaccaro, G.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 67 - 67
  • [4] Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)
    Reinacher-Schick, A. C.
    Kubicka, S.
    Freier, W.
    Arnold, D.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Graeven, U.
    Schmoll, H.
    Schmiegel, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II study of the A-ICOX regimen [bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox)] for untreated advanced colorectal cancer (CRC)
    Ramanathan, R. K.
    Rajasenan, K.
    Crandall, T.
    Balaban, E. P.
    Pinkerton, R. A.
    Kane, P.
    Potter, D. M.
    Dranko, S.
    Schmotzer, A.
    Lembersky, B. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.
    Bendell, J. C.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Schaffer, S.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 156S - 156S
  • [7] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    [J]. CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [8] Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
    Stein, Alexander
    Kretzschmar, Albrecht
    Behringer, Dirk
    Wolff, Thomas
    Zimber, Joachim
    Hegewisch-Becker, Susanna
    Kettner, Erika
    Pflueger, Karl-Heinz
    Kirsch, Andreas
    Arnold, Dirk
    [J]. BMC CANCER, 2013, 13
  • [9] Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
    Alexander Stein
    Albrecht Kretzschmar
    Dirk Behringer
    Thomas Wolff
    Joachim Zimber
    Susanna Hegewisch-Becker
    Erika Kettner
    Karl-Heinz Pflüger
    Andreas Kirsch
    Dirk Arnold
    [J]. BMC Cancer, 13
  • [10] Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: results of a phase II trial
    Bendell, J.
    Yu, D.
    Hurwitz, H.
    Morse, M.
    Blobe, G.
    Gockerman, J.
    Odogwu, L.
    Mahon, M.
    Truax, R.
    Fernando, N.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 189
12345